Please try another search
Galectin Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin, for the prevention of esophageal varices.
Name | Age | Since | Title |
---|---|---|---|
Gilbert S. Omenn | 79 | 2009 | Independent Director |
Richard E. Uihlein | 76 | 2017 | Independent Chairman |
Kevin D. Freeman | 59 | 2011 | Independent Vice Chairman of the Board |
Joel Lewis | 51 | 2017 | President, CEO & Director |
Gilbert F. Amelio | 78 | 2009 | Independent Director |
Richard A. Zordani | 48 | 2020 | Independent Director |
Anatole A. Klyosov | 76 | 2000 | Co-founder & Member of the Scientific Board |
Marc Rubin | 68 | 2011 | Independent Director |
Arun J. Sanyal | - | - | Member of Clinical Advisory Board |
Brent Tetri | - | - | Member of Clinical Advisory Board |
Thomas D. Schiano | - | - | Member of Clinical Advisory Board |
Ram Subramanian | - | - | Member of Clinical Advisory Board |
Stephen A. Harrison | - | - | Member of Clinical Advisory Board |
Mohammad Siddiqui | - | - | Member of Clinical Advisory Board |
Elissa J. Schwartz | 52 | 2020 | Independent Director |
Kary Eldred | 49 | 2018 | Independent Director |
Kevin H. Mayo | - | - | Member of the Scientific Board |
Eric Lawitz | - | - | Member of Clinical Advisory Board |
Naga Chalasani | - | - | Member of Clinical Advisory Board |
Benjamin S. Carson | 72 | 2023 | Independent Director |
Harold H. Shlevin | 74 | 2012 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review